Translational endpoints in fragile X syndrome

Area of Science:

• Neuroscience
• Genetics
• Developmental Biology

Background:

• Fragile X syndrome (FXS) is a genetic disorder causing intellectual disability, linked to the FMR1 gene.
• The FMR1 gene's CGG repeat expansion leads to hypermethylation and silencing, preventing fragile X mental retardation protein (FMRP) production.
• FMRP is crucial for neuronal function, particularly synaptic plasticity and local protein synthesis.

Purpose of the Study:

• To review the cellular functions of FMRP and its implications for FXS.
• To discuss the challenges in identifying reliable outcome measures for preclinical FXS studies.
• To summarize clinical trials investigating therapeutic interventions for FXS-related deficits.

Main Methods:

• Review of scientific literature on FXS, FMRP function, and therapeutic strategies.
• Analysis of preclinical studies utilizing cellular models and Fmr1 knockout mice.
• Examination of clinical trial data for FXS treatments.

Main Results:

• FMRP deficiency in neurons is the direct cause of intellectual disability in FXS.
• Advancements in understanding FMRP's cellular role identify potential therapeutic targets.
• Preclinical models are essential for validating outcome measures and testing interventions.
• Clinical studies explore various drugs to address intellectual and behavioral deficits in FXS patients.

Conclusions:

• Targeting FMRP's cellular functions offers promising therapeutic avenues for FXS.
• Rigorous preclinical studies are vital for developing effective FXS treatments.
• Ongoing clinical trials aim to improve outcomes for individuals with Fragile X syndrome.